Cantargia (CANTA) Stock Overview
A biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CANTA Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cantargia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.57 |
| 52 Week High | SEK 6.59 |
| 52 Week Low | SEK 1.56 |
| Beta | 1.59 |
| 1 Month Change | -7.92% |
| 3 Month Change | -27.38% |
| 1 Year Change | -45.39% |
| 3 Year Change | -62.95% |
| 5 Year Change | -93.03% |
| Change since IPO | -82.56% |
Recent News & Updates
CANTA: IL1RAP Data And New Trial Will Support Future Repricing
Analysts have reduced their Cantargia price target from SEK10.50 to SEK8.25, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. What’s in the News for Cantargia Cantargia published preclinical and clinical findings from the nadunolimab CANFOUR trial in JCI Insight, highlighting the role of IL1RAP in pancreatic ductal adenocarcinoma and its potential use as a therapeutic target and predictive biomarker.
CANTA: Equity Raise Will Support Advancing High-Risk MDS Opportunity
Analysts have cut their SEK fair value estimate for Cantargia from SEK 6.00 to SEK 4.50. This reflects updated assumptions for weaker revenue growth, a higher discount rate and a less favourable future P/E, which are partly offset by slightly stronger projected profit margins.CANTA: Recent Equity Raises Will Support Advancing High-Risk MDS And AML Trial
The Cantargia analyst price target has been revised from SEK 7.0 to SEK 6.0 as analysts now factor in softer revenue growth assumptions, a slightly higher discount rate and a lower future P/E multiple, partially offset by a higher projected profit margin. What’s in the News for Cantargia Cantargia has completed a follow on equity offering of SEK 75.0 million, issuing 21,746,898 ordinary shares and 11,586,435 ordinary shares at SEK 2.25 per share, via a rights offering.Recent updates
CANTA: IL1RAP Data And New Trial Will Support Future Repricing
Analysts have reduced their Cantargia price target from SEK10.50 to SEK8.25, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. What’s in the News for Cantargia Cantargia published preclinical and clinical findings from the nadunolimab CANFOUR trial in JCI Insight, highlighting the role of IL1RAP in pancreatic ductal adenocarcinoma and its potential use as a therapeutic target and predictive biomarker.CANTA: Equity Raise Will Support Advancing High-Risk MDS Opportunity
Analysts have cut their SEK fair value estimate for Cantargia from SEK 6.00 to SEK 4.50. This reflects updated assumptions for weaker revenue growth, a higher discount rate and a less favourable future P/E, which are partly offset by slightly stronger projected profit margins.CANTA: Recent Equity Raises Will Support Advancing High-Risk MDS And AML Trial
The Cantargia analyst price target has been revised from SEK 7.0 to SEK 6.0 as analysts now factor in softer revenue growth assumptions, a slightly higher discount rate and a lower future P/E multiple, partially offset by a higher projected profit margin. What’s in the News for Cantargia Cantargia has completed a follow on equity offering of SEK 75.0 million, issuing 21,746,898 ordinary shares and 11,586,435 ordinary shares at SEK 2.25 per share, via a rights offering.IL1RAP Platform Risks And Shifting Cancer Standards Will Eventually Reveal Hidden Upside
Catalysts About Cantargia Cantargia is a biotechnology company focused on IL1RAP targeted therapies in oncology and inflammatory diseases. What are the underlying business or industry changes driving this perspective?Cantargia AB (publ) Just Reported A Surprise Profit And Analysts Updated Their Estimates
It's been a mediocre week for Cantargia AB (publ) ( STO:CANTA ) shareholders, with the stock dropping 12% to kr3.17 in...Cantargia (STO:CANTA) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...We Think Cantargia (STO:CANTA) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Can Cantargia (STO:CANTA) Afford To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...Shareholder Returns
| CANTA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -1.9% | -1.8% | -0.7% |
| 1Y | -45.4% | 19.9% | 12.3% |
Return vs Industry: CANTA underperformed the Swedish Biotechs industry which returned 19.9% over the past year.
Return vs Market: CANTA underperformed the Swedish Market which returned 12.3% over the past year.
Price Volatility
| CANTA volatility | |
|---|---|
| CANTA Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in SE Market | 10.6% |
| 10% least volatile stocks in SE Market | 2.9% |
Stable Share Price: CANTA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CANTA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 22 | Hilde Steineger | cantargia.com |
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.
Cantargia AB (publ) Fundamentals Summary
| CANTA fundamental statistics | |
|---|---|
| Market cap | SEK 392.56m |
| Earnings (TTM) | SEK 167.38m |
| Revenue (TTM) | SEK 317.31m |
Is CANTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CANTA income statement (TTM) | |
|---|---|
| Revenue | SEK 317.31m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 317.31m |
| Other Expenses | SEK 149.92m |
| Earnings | SEK 167.38m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 25, 2026
| Earnings per share (EPS) | 0.67 |
| Gross Margin | 100.00% |
| Net Profit Margin | 52.75% |
| Debt/Equity Ratio | 0% |
How did CANTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/17 17:58 |
| End of Day Share Price | 2026/09/17 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cantargia AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arvid Necander | Carnegie Investment Bank AB |
| Soo Romanoff | Edison Investment Research |
| Sara Nik | H.C. Wainwright & Co. |